On March 19, 2021, Numinus Wellness Inc. (TSXV:NUMI) (“Numinus” or the “Company”) announced the closing of its bought deal financing of 28,000,000 units (the “Units”) at a price of $1.25 per Unit for total gross proceeds of $35 million (the “Offering”). Numinus is creating an ecosystem of health solutions centered around the safe, evidence-based and accessible use of psychedelic-assisted psychotherapies.
The Offering was conducted by Eight Capital and Canaccord Genuity Corp. (together, the “Underwriters”). The Underwriters also exercised their over-allotment option in full to purchase an additional 4,200,000 Units for additional gross proceeds of $5.25 million. Including the proceeds from the exercise of the over-allotment option, the total gross proceeds of the Offering are $40.25 million with an aggregate of 32,200,000 Units issued.
Numinus plans to use the net proceeds of the Offering to acquire and build local community clinics and flagship facilities offering a wide variety of amenities, including psychedelic-assisted psychotherapy when regulated. The Company anticipates partnering with leading academic, corporate and non-profit groups on clinical and compassionate access trials and continuing to innovate in psychedelic-assisted psychotherapy training, protocols and policies.
Miller Thomson advised Numinus in the Offering with a team comprised of Rory Godinho, Lucy Schilling, Kathy Tang, Bruno Caron, Gosia Piasecka and Rachel Thorson (Capital Markets); Lesley Kim and Colleen Ma (Corporate Tax).
